Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Users can note which content they would like to view more frequently. Instagram is handing users some control in deciding what content they see. The social media giant is allowing users to have a say ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

A vast, star-forming cloud in the constellation Orion has been unveiled in stunning detail by the European Space Agency's Euclid Space Telescope, offering a rare look at the turbulent birthplace of ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Instagram is back with a new feature that will allow users to "tune" their algorithm to only display the content they prefer to see, which will be first made available to Reels. The feature is still ...